Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
| Revenue (TTM) | $4.62T |
| Gross Profit (TTM) | $2.98T |
| EBITDA | $1.25T |
| Operating Margin | 16.50% |
| Return on Equity | -2.26% |
| Return on Assets | 2.69% |
| Revenue/Share (TTM) | $1462.74 |
| Book Value | $14.36 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 0.01 |
| EV/Revenue | 2.895 |
| EV/EBITDA | 22.77 |
| Quarterly Earnings Growth (YoY) | -9.80% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $3.19B |
| Float | $3.16B |
| % Insiders | 0.06% |
| % Institutions | 3.30% |
Volatility is currently contracting
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SBLK, TAK and STBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 17, 2026.
TAK, VLO, PFX, SBLK and RELY have been added to the Zacks Rank #1 (Strong Buy) List on August 17, 2026.
Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher taxes and lower operating cash flow due to mounting receivables. Orzeyful's FDA approval is promising, but its commercial impact is likely limited compared to Entyvio; pipeline drugs like zasocitinib offer longer-term potential, but how much is as yet uncertain.
Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript
Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio.
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter.
Japanese drugmaker Takeda Pharmaceutical's dengue vaccine QDENGA has been approved by India's drug regulator, making it the first dengue vaccine to be approved in the country, the company's Indian unit said on Monday.
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia's plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TAK and any ticker you trade — then tracks every position and per-strategy win rate.
